StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $2.50 price objective on shares of VolitionRx in a research note on Wednesday, March 27th.

VolitionRx Stock Up 11.3 %

VNRX stock opened at $0.89 on Friday. The firm has a 50 day moving average of $0.85 and a 200 day moving average of $0.84. The stock has a market capitalization of $73.05 million, a PE ratio of -1.75 and a beta of 1.35. VolitionRx has a 52 week low of $0.55 and a 52 week high of $2.10.

VolitionRx (NYSE:VNRX) last released its earnings results on Monday, March 25th. The company reported ($0.11) EPS for the quarter. The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.50 million. On average, equities research analysts expect that VolitionRx will post -0.4 earnings per share for the current year.

Institutional Trading of VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new stake in VolitionRx Limited (NYSE:VNRX) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent reporting period. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.